GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Samjin Pharmaceutical Co 005500.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

20,350

-0.49%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩309.13bn

FY2016FY2025

Net income

₩24.17bn

FY2016FY2025

Free cash flow

₩9.62bn

FY2016FY2025

Shareholders' equity

₩290.39bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩309.13bn₩308.35bn₩292.13bn₩274.03bn₩250.07bn₩235.16bn₩241.93bn₩260.02bn₩245.27bn₩239.31bn
Gross profit₩125.08bn₩128.97bn₩116.68bn₩117.73bn₩117.83bn₩110.52bn₩120.71bn₩142.78bn₩135.98bn₩129.35bn
Research and development₩4.39bn₩4.50bn₩4.17bn₩3.66bn₩2.58bn₩1.51bn₩2.60bn₩3.74bn₩3.65bn₩2.80bn
Operating income₩26.78bn₩48.33bn₩20.48bn₩26.84bn₩33.91bn₩32.24bn₩44.90bn₩59.54bn₩46.95bn₩42.06bn
Net income₩24.17bn₩39.23bn₩18.91bn₩21.89bn₩28.40bn₩27.88bn₩11.88bn₩25.53bn₩35.80bn₩30.17bn
Diluted earnings per share1,971.913,200.841,542.651,786.222,317.362,274.54969.302,082.562,920.422,423.08

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩470.53bn₩425.17bn₩419.90bn₩406.56bn₩332.50bn₩269.03bn₩244.15bn₩250.27bn₩241.85bn₩227.57bn
Total liabilities₩180.14bn₩163.51bn₩154.54bn₩130.69bn₩98.33bn₩55.58bn₩46.68bn₩44.95bn₩48.38bn₩57.88bn
Debt₩28.50bn—₩4.17bn₩42.50bn₩39.83bn₩6.74bn——₩4.00bn₩9.00bn
Shareholders' equity₩290.39bn₩261.66bn₩265.37bn₩275.34bn₩234.17bn₩213.46bn₩197.47bn₩205.32bn₩193.47bn₩169.69bn
Shares outstanding12m12m12m12m12m12m12m12m12m12m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩24.11bn₩38.15bn₩8.33bn₩17.29bn₩23.97bn₩23.86bn₩23.63bn₩30.08bn₩37.28bn₩48.66bn
Capital spending−₩14.49bn−₩18.34bn−₩20.72bn−₩35.50bn−₩74.60bn−₩30.60bn−₩12.04bn−₩8.24bn−₩8.86bn−₩7.80bn
Free cash flow₩9.62bn₩19.81bn−₩12.39bn−₩18.20bn−₩50.64bn−₩6.74bn₩11.59bn₩21.85bn₩28.42bn₩40.86bn
Dividends paid−₩9.81bn−₩10.22bn−₩10.58bn−₩9.84bn−₩9.84bn−₩9.84bn−₩9.84bn−₩9.84bn−₩8.72bn−₩7.47bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩79.63bn₩68.07bn₩80.53bn₩83.13bn₩74.61bn₩70.86bn₩84.49bn₩80.55bn
Gross profit₩27.57bn₩25.03bn₩32.15bn₩34.04bn₩31.05bn₩27.85bn₩38.07bn₩33.09bn
Operating income₩7.15bn₩3.59bn₩6.17bn₩9.78bn₩7.95bn₩4.84bn₩9.18bn₩9.19bn
Net income₩6.10bn₩1.39bn₩8.93bn₩6.84bn₩4.68bn₩3.72bn₩6.85bn₩4.49bn
Diluted earnings per share497.55113.71728.71557.77381.74303.68558.89366.44
Cash from operations₩14.58bn₩12.49bn₩10.06bn−₩1.43bn₩10.63bn₩4.85bn−₩3.16bn₩5.17bn
Capital spending−₩1.55bn−₩2.60bn−₩3.59bn−₩2.79bn−₩3.78bn−₩4.34bn−₩6.52bn−₩2.91bn
Free cash flow₩13.03bn₩9.88bn₩6.47bn−₩4.22bn₩6.84bn₩518.0m−₩9.67bn₩2.26bn
Total assets₩476.87bn₩452.49bn₩470.53bn₩449.14bn₩429.15bn₩425.09bn₩425.17bn₩432.92bn
Debt₩28.00bn₩28.00bn₩28.50bn₩28.50bn₩29.00bn₩30.00bn——
Shareholders' equity₩298.77bn₩277.59bn₩290.39bn₩264.51bn₩258.27bn₩252.05bn₩261.66bn₩282.53bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.1%5.6%3.6%
Operating income-0.1%-3.6%-2.9%
Net income3.4%-2.8%-1.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin41.1%41.3%43.0%47.5%
Operating margin12.2%10.3%11.3%14.6%
Net margin10.3%8.8%9.6%10.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings10.05.714.014.411.312.025.719.312.314.3
Price to sales0.80.70.91.11.31.41.31.91.81.8

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2024.

FY2025FY2024FY2023FY2022FY2021FY2019FY2018FY2017
Paid in the year800.00800.00800.00800.00800.001,600.00800.00700.00
  • 1.031-for-1 split · 29 Dec 2010
  • 1.031-for-1 split · 29 Dec 2009
  • 1.031-for-1 split · 29 Dec 2008
  • 5-for-1 split · 30 Apr 2008
  • 1.021-for-1 split · 27 Dec 2007
  • 1.04-for-1 split · 3 Jan 1992

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.